Doing it wrong meme10/14/2023 Last quarter, operating expenses came in at $21.8 million, up moderately from the prior quarter ($17.9 million), and up tremendously from the prior year’s quarter ($11 million). Investors took issue with low revenue levels and rising operating expenses. Yet again, this wasn’t enough to get investors excited again about BNGO stock. These strong results are due to increased installations of its Saphyr optical genome mapping (OGM) instrument. This was the sixth quarter in a row that the company has beat analyst revenue estimates. Just like what played out last quarter, this early stage company has once again posted triple-digit-percentage revenue growth. 30, Bionano generated $4.7 million in sales, up 112% year-over-year.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |